Nancy Lee

🚨 Anthropic just showed a 27-minute workshop on how to actually do prompts for Claude. Taught by the people who built it. Free. No registration. No paywall. I've seen $300 courses that don't cover what they teach in the first 8 minutes. Watch it and bookmark it now.

@xrtGenomics @DrSpratticus @seanmcbride @SJFrankMD @EChrisDee @imrtlee @CJTsaiMDPhD @DavidSherMD @seanmmcbride @jdschoenfeld1 @HeadNeckMD @lucmorrisnyc On paper, protons have a place in reirradiation. But in reality, the whole reirradiation space is built on a house of cards with EQD2 conversions and heterogeneous fractionation schemes. The truth is, we don't really know.

The authors of a new Perspective argue that clinicians are rightly expected to disclose their gaps in knowledge or their inability to forecast an outcome. Yet emerging AI tools often cannot, or will not, do the same. Read the Perspective by @AndreaSikora, PharmD, MSCR, Leo A. Celi, MD, MPH, and Raja-Elie E. Abdulnour, MD (@BageLeMage): nej.md/4fgdg0D

Revolutionary work by @jaydetsky @SahgalArjun & the @Sunnybrook @UofTDRO team for #glioblastoma #btsm #radonc now in @TheLancetOncol! Daily adapt-to-position, weekly adapt-to-shape with 5 mm CTV margins using @Elekta @mr_linac. Eye-opening experience contributing to this work.

🌍🌎🌏 Thank you @JNCCN for the chance to write an accompanying editorial in response to excellent work from Sim et al on #family and #caregiver #financial #toxicity in global settings 🙏 Grateful to Dr Adrian E Go for his insights and expertise 🔗 jnccn.org/view/journals/…

Great letter by @SeanMcbride laying out real concerns with the OS claim in @SJFrankMD's proton vs. photon oropharynx trial. Compelling enough that Yingzhi Wu and @EChrisDee pulled our own data. We see no OS difference between protons and photons. Together with UK TORPEdO RCT, this adds to the concern that the randomized trial’s OS finding may be hypothesis-generating rather than causal.

We just found out our work will be presented at the ASTRO 2026 Plenary Session. Not a poster. Not a breakout. The Plenary. Low-dose radiotherapy for knee osteoarthritis with sustained clinical benefit, MRI-confirmed outcomes, 13-year randomized data. Stay tuned. @ASTRO_org

Our letter to the editor in The Lancet critiquing the MD Anderson-led trial of protons v photons for OPC. Appreciate @SJFrankMD's well thought out response. I think we can all agree on two points: 1) Steve deserves major kudos for bringing level 1 evidence to the debate on protons v photons for OPC. These trials are extraordinarily difficult to run, and Steve, et al pulled it off. Well done! 2) Longer term follow-up from TORPEdO will help tease out the extent to which protons improves OS in OPC. @CJTsaiMDPhD @drlorenmell @xrtGenomics @DavidSherMD #radonc #hncsm thelancet.com/journals/lance…

Our work identifying a new spinal cord constraint for spine SBRT was published yesterday in @JAMAOnc @DanHigginsonMD. Here, a thread: jamanetwork.com/journals/jamao…

A blast to have @imrtlee (@MSKCancerCenter) as our @Sunnybrook #radonc Dembo Visiting Professor share her vision + trailblazing path towards personalization of cancer care. A beacon of joy and creativity in head & neck cancer and beyond! @SahgalArjun @mctjong @UofTDRO @ldawsonmd

@DavidSherMD Great summary as always 🙏🏾… Can we just de-escalate (dose, volume, fractions) and get rid of most of these problems?! 🙃

TORPEdO was an incredible effort by the investigators and patients, and the paper analyzes the results extraordinarily well. Given the normalization of outcomes over a very short period of time following treatment, plus the difference in weight loss without any sacrifice in a very low risk of g-tube dependence over time, I agree with the paper’s conclusion: "In health-care settings where IMPT is not used routinely for oropharyngeal squamous cell carcinoma, IMRT remains the standard-of-care.” Especially since IMRT in 2026 is markedly better than the delivered treatments in the trial, it is hard to see how IMRT shouldn’t always be the standard-of-care. The key is not stopping there. It is critical to remember that in both arms, about 50% or more of patients reported altered appearance, taste, swallowing and saliva: we need to do better! And additional improvement clearly will require something more meaningful than protons or photons. Total dose, elective dose, and elective volumes all need to be personalized and optimized. Let's go!

👋👋👋 Congrats to the investigators for the long awaited publication of this well-executed trial. Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, ran... sciencedirect.com/science/articl… @seanmmcbride @DavidSherMD @KaramLab

Come for the critically important data on protons for oropharyngeal cancer, stay for the beautifully written paper. TORPEdO is out, and it is fascinating and instructive. I will warn you upfront that this is a long thread, but there is a lot here to discuss! thelancet.com/journals/lance…

Researchers have published the recipe for an artificial-intelligence model that reviews the scientific literature better than some major LLMs are able to, and gets the citations correct as often as human experts do go.nature.com/4r3fiEC

New @CellCellPress The hallmarks of cancer, refined from the original concepts 25 years ago, as an outgrowth of our expanding knowledge base cell.com/cell/fulltext/…

🙏 Thank you @ASCOPost for featuring our @Annals_Oncology paper "Machine learning reveals country-specific drivers of global cancer outcomes" led by @MilitSPatel 🔗 ascopost.com/news/january-2… @MSK_RadOnc @PCFnews

RNA-binding proteins and ribonucleoproteins as determinants of immunity dlvr.it/TQMKKq

Our review is highlighted by the cover of the current issue of @TrendsImmuno -The lingering shadow of epidemics: post-acute sequelae across history by Christine Miller and @jannamoen. Please read (open access)👇🏼 cell.com/trends/immunol…

RNA modification systems as therapeutic targets nature.com/articles/s4157… rdcu.be/eZdRG This Review in the January issue discusses the disease associations of proteins that regulate RNA modifications and advances in the development of therapeutic inhibitors